Who should sponsor sleep disorders pharmaceutical trials?

Journal of Clinical Sleep Medicine

Volumn 3, Issue 7, 2007, Pages 671-673

  Kripke, Daniel F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; ESZOPICLONE; HYPNOTIC AGENT; MELATONIN; PSYCHOTROPIC AGENT; ZOLPIDEM;

CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE THERAPY; COUGHING; DEPRESSION; DRUG FATALITY; DRUG INDUSTRY; DRUG MARKETING; EDITORIAL; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INSOMNIA; NARCOLEPSY; NEOPLASM; OTITIS MEDIA; PHARMACEUTICAL CARE; PHARYNGITIS; RHINITIS; SINUSITIS; SLEEP APNEA SYNDROME; SLEEP DISORDER; URINARY TRACT INFECTION;

EID: 38849201930     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27020     Document Type: Editorial

References (19)

1. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28:1049-57.
2. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50.
3. Kelly RE, Jr., Cohen LJ, Semple RJ, et al. Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med 2006;36:1647-56.
4. Perlis RH, Perils CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162:1957-60.
5. Brown A, Kraft D, Schmitz SM, et al. Association of industry sponsorship to published outcomes in gastrointestinal clinical research. Clin Gastroenterol Hepatol 2006;4:1445-51.
6. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 2004;38:579-85.
7. Bodenheimer T. Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342:1539-44.
8. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
9. Giles J. Drug trials: stacking the deck. Nature 2006;440:270-2.
10. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169
11. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138.
12. Kripke DF. Greater incidence of depression with hypnotics than with placebo. BMC Psychiatry 2007;7:42.
13. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9.
14. Kripke DF. Evidence that new hypnotics cause cancer. http://repositories. cdlib.org/ucsdpsych/3. 8-15-2006. Department of Psychiatry, UCSD, Paper 3.
15. Scharf MB, Black J, Hull S, Landin R, Farber R. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep 2007;30:743-52.
16. Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney Int 2007;72:1388-93.
17. Kripke DF. Chronic hypnotic use: Deadly risks, doubtful benefit. Sleep Med Rev 2000;4:5-20.
18. NIOM. Sleeping Pills, Insomnia, and Medical Practice. Washington, DC: National Academy of Sciences, 1979.
19. Ahmed I, Soares Souza KV, Seifas R, Adams CE. Randomized controlled trials in Arch Gen Psychiatry (1959-1995): a prevalence study. Arch Gen Psychiatry 1998;55:754-55.